Understanding how changes in gene regulation affect lung disease
Official title: Maladaptive epigenetic control of MUC5B transcription in pulmonary fibrosis
Funded at University of Colorado Denver · NIH-10815869 · Data updated 2026-11-12
This study is looking at how changes in our genes might affect a specific gene linked to idiopathic pulmonary fibrosis (IPF), a serious lung disease, by comparing lung cells from healthy people and those with IPF to better understand what causes the disease and its symptoms.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | July 1, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $554,488 |
| NIH project number | 5P01HL162607-02 |
| Project ID | NIH-10815869 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis or those at high risk due to genetic factors.
✕Less likely to help
Patients with other forms of lung disease or those without a genetic predisposition to IPF may not benefit from this research.
What this research studies
This research investigates the mechanisms behind increased expression of the MUC5B gene, which is linked to idiopathic pulmonary fibrosis (IPF), a severe lung disease. The team will analyze how epigenetic changes influence MUC5B expression in lung cells from both healthy individuals and those with IPF. By exploring these molecular processes, the research aims to uncover the factors that contribute to the development of IPF and its associated symptoms. The study will involve advanced techniques like ATAC sequencing to assess chromatin accessibility and gene regulation.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating or preventing idiopathic pulmonary fibrosis.
How similar studies have gone: Previous research has shown promising results in understanding gene regulation in lung diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Gerber, Anthony N — University of Colorado Denver
- Study coordinator: Gerber, Anthony N
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.